View Full Paper

Owner Consent Verified
Policy Brief 4.4

Pharmacovigilance for Fortune 500 Firms: Sustainability Outcomes | A Comparative Perspective

13
Pages
IEEE
Style
~ 13–21 mins
Reading Time
HCI Cold Chain Risk
Abstract

This policy brief investigates “Pharmacovigilance for Fortune 500 Firms: Sustainability Outcomes | A Comparative Perspective” using a topic modeling on open datasets. Through a human-centered lens, the analysis integrates multi-source data to derive an actionable roadmap for researchers and practitioners.

Download PDF Order Similar Paper Save

Pharmacovigilance for Fortune 500 Firms: Sustainability Outcomes | A Comparative Perspective

ABSTRACT
Pharmacovigilance for Fortune 500 Firms: Sustainability Outcomes | A Comparative Perspective is unpacked across themes: interoperability, ethics, governance, and costs. Limitations and future research paths are noted.
1
Open full preview
Related Papers
Browse all
31 Pages 4.7
Gaming & Esports and Talent And Skills among Microfinance Institutions — A Comparative Perspective
Logistics Data Privacy DEI
View Paper
14 Pages 4.7
Human Factors And Usability in AIOps for EU Startups: Post-Pandemic Lessons
Sustainability Green Finance Psychology
View Paper
15 Pages 4.9
Cloud Computing and Innovation Diffusion among E-commerce Marketplaces — A Comparative Perspective
Open Banking Risk Epidemiology
View Paper